Los Angeles Capital Management LLC Grows Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Los Angeles Capital Management LLC boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 23.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 33,656 shares of the medical instruments supplier’s stock after buying an additional 6,320 shares during the period. Los Angeles Capital Management LLC’s holdings in LeMaitre Vascular were worth $3,126,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. CANADA LIFE ASSURANCE Co lifted its stake in LeMaitre Vascular by 44.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after purchasing an additional 6,875 shares during the last quarter. Quantbot Technologies LP grew its holdings in shares of LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after purchasing an additional 6,669 shares during the last quarter. Quadrature Capital Ltd increased its position in shares of LeMaitre Vascular by 129.4% during the first quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock worth $1,484,000 after purchasing an additional 12,654 shares in the last quarter. Janus Henderson Group PLC grew its stake in LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after buying an additional 47,218 shares during the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in LeMaitre Vascular during the second quarter worth approximately $1,010,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Down 2.1 %

NASDAQ LMAT opened at $103.26 on Wednesday. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of 56.79, a PEG ratio of 2.55 and a beta of 0.89. The business’s 50 day moving average is $90.96 and its two-hundred day moving average is $84.86. LeMaitre Vascular, Inc. has a 12-month low of $48.66 and a 12-month high of $106.49.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.33 earnings per share. Equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LMAT shares. Oppenheimer restated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. Barrington Research raised their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Lake Street Capital began coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Finally, StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.